

Camillio Porta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8335732/publications.pdf>

Version: 2024-02-01

381
papers

36,559
citations

24978

57
h-index

3476

182
g-index

392
all docs

392
docs citations

392
times ranked

32523
citing authors

#	ARTICLE	IF	CITATIONS
1	Sorafenib in Advanced Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 378-390.	13.9	12,004
2	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 378, 1277-1290.	13.9	3,334
3	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. <i>Lancet, The</i> , 2008, 372, 449-456.	6.3	2,848
4	Targeting PI3K/Akt/mTOR Signaling in Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 64.	1.3	1,077
5	Phase 3 trial of everolimus for metastatic renal cell carcinoma. <i>Cancer</i> , 2010, 116, 4256-4265.	2.0	1,039
6	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 829-841.	13.9	961
7	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1289-1300.	13.9	956
8	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet, The</i> , 2019, 393, 2404-2415.	6.3	778
9	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. <i>Journal of Hepatology</i> , 2012, 57, 821-829.	1.8	736
10	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2019, 20, 1370-1385.	5.1	594
11	Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. <i>Lancet Oncology, The</i> , 2009, 10, 757-763.	5.1	571
12	Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. <i>Lancet Oncology, The</i> , 2013, 14, 55-63.	5.1	522
13	Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1412-1418.	0.8	381
14	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. <i>ESMO Open</i> , 2020, 5, e001079.	2.0	343
15	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2020, 21, 1574-1588.	5.1	324
16	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology, The</i> , 2018, 19, 682-693.	5.1	285
17	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 286-296.	5.1	239
18	Choosing the right cell line for renal cell cancer research. <i>Molecular Cancer</i> , 2016, 15, 83.	7.9	205

#	ARTICLE	IF	CITATIONS
19	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2445-2452.	3.2	193
20	Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. <i>Lancet Oncology</i> , The, 2020, 21, 95-104.	5.1	160
21	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
22	Receptor Activator of NF- κ B (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients. <i>PLoS ONE</i> , 2011, 6, e19234.	1.1	157
23	Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. <i>Targeted Oncology</i> , 2016, 11, 143-148.	1.7	152
24	Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 1287-1298.	1.3	133
25	Sunitinib in metastatic renal cell carcinoma patients with brain metastases. <i>Cancer</i> , 2011, 117, 501-509.	2.0	126
26	A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer. <i>European Urology</i> , 2015, 67, 100-110.	0.9	122
27	Treatment selection in metastatic renal cell carcinoma: expert consensus. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 327-337.	12.5	121
28	Store-Operated Ca ²⁺ Entry Is Remodelled and Controls In Vitro Angiogenesis in Endothelial Progenitor Cells Isolated from Tumoral Patients. <i>PLoS ONE</i> , 2012, 7, e42541.	1.1	121
29	Toxicities of Targeted Therapy and Their Management in Kidney Cancer. <i>European Urology</i> , 2011, 59, 526-540.	0.9	119
30	Expression pattern of receptor activator of NF κ B (RANK) in a series of primary solid tumors and related bone metastases. <i>Journal of Cellular Physiology</i> , 2011, 226, 780-784.	2.0	118
31	Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 888-898.	5.1	114
32	The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?. <i>Frontiers in Immunology</i> , 2020, 11, 574271.	2.2	112
33	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. , 2019, 7, 99.		110
34	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. <i>JAMA Network Open</i> , 2021, 4, e2021869.	2.8	104
35	Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. <i>Cancer</i> , 2022, 128, 2085-2097.	2.0	103
36	Renal effects of targeted anticancer therapies. <i>Nature Reviews Nephrology</i> , 2015, 11, 354-370.	4.1	95

#	ARTICLE	IF	CITATIONS
37	Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. <i>Kidney International</i> , 2010, 77, 809-815.	2.6	93
38	Bortezomib Inhibits Nuclear Factor- κ B-Dependent Survival and Has Potent In vivo Activity in Mesothelioma. <i>Clinical Cancer Research</i> , 2007, 13, 5942-5951.	3.2	90
39	The role of the cell-cell interactions in cancer progression. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 283-296.	1.6	89
40	Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGET. <i>European Journal of Cancer</i> , 2010, 46, 2432-2440.	1.3	84
41	Phosphatidylinositol-3-Kinase/Akt Signaling Pathway and Kidney Cancer, and the Therapeutic Potential of Phosphatidylinositol-3-Kinase/Akt Inhibitors. <i>Journal of Urology</i> , 2009, 182, 2569-2577.	0.2	83
42	Non-Melanoma Skin Cancers: Biological and Clinical Features. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5394.	1.8	83
43	SV40-Dependent AKT Activity Drives Mesothelial Cell Transformation after Asbestos Exposure. <i>Cancer Research</i> , 2005, 65, 5256-5262.	0.4	81
44	Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. <i>BJU International</i> , 2011, 108, E250-E257.	1.3	79
45	Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients. <i>Oncology</i> , 2013, 84, 115-122.	0.9	77
46	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. <i>Annals of Surgical Oncology</i> , 2015, 22, 2094-2100.	0.7	72
47	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. <i>European Urology</i> , 2019, 76, 861-867.	0.9	71
48	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , 2019, 123, 98-105.	1.3	70
49	The adjuvant treatment of kidney cancer: a multidisciplinary outlook. <i>Nature Reviews Nephrology</i> , 2019, 15, 423-433.	4.1	68
50	The Presence of Simian-Virus 40 Sequences in Mesothelioma and Mesothelial Cells Is Associated with High Levels of Vascular Endothelial Growth Factor. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2002, 26, 189-193.	1.4	67
51	Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey. <i>PLoS ONE</i> , 2013, 8, e83026.	1.1	66
52	Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts. <i>Clinical Cancer Research</i> , 2008, 14, 541-548.	3.2	65
53	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 10.	3.5	65
54	Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. <i>European Journal of Cancer</i> , 2016, 69, 226-235.	1.3	65

#	ARTICLE	IF	CITATIONS
73	Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. <i>Anticancer Research</i> , 2013, 33, 3487-94.	0.5	53
74	Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. <i>European Urology</i> , 2020, 77, 449-453.	0.9	52
75	Raltitrexed+Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. <i>Lung Cancer</i> , 2005, 48, 429-434.	0.9	51
76	Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site. <i>Cancer</i> , 2006, 107, 2898-2905.	2.0	51
77	Store-Operated Ca ²⁺ Entry Does Not Control Proliferation in Primary Cultures of Human Metastatic Renal Cellular Carcinoma. <i>BioMed Research International</i> , 2014, 2014, 1-19.	0.9	51
78	Integration of Lipidomics and Transcriptomics Reveals Reprogramming of the Lipid Metabolism and Composition in Clear Cell Renal Cell Carcinoma. <i>Metabolites</i> , 2020, 10, 509.	1.3	51
79	Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 609-609.	0.8	51
80	Determination of free and total (free plus protein-bound) melatonin in plasma and cerebrospinal fluid by high-performance liquid chromatography with fluorescence detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 774, 17-24.	1.2	49
81	Expression of pERK and VEGFR ² in advanced hepatocellular carcinoma and resistance to sorafenib treatment. <i>Liver International</i> , 2015, 35, 2001-2008.	1.9	49
82	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015, 10, 517-522.	1.7	49
83	Insulin-like growth factor-1 signaling in renal cell carcinoma. <i>BMC Cancer</i> , 2016, 16, 453.	1.1	49
84	Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 547-547.	0.8	49
85	Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity. <i>Future Oncology</i> , 2015, 11, 39-50.	1.1	48
86	Deficient Natural Killer Cell NKG30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 1165-1179.	3.6	48
87	Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.. <i>Journal of Clinical Oncology</i> , 2021, 39, 308-308.	0.8	48
88	Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence. <i>Therapeutic Advances in Urology</i> , 2017, 9, 195-207.	0.9	47
89	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. <i>Kidney International</i> , 2019, 96, 555-567.	2.6	47
90	Patients with sarcomatoid renal cell carcinoma " re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020, 136, 195-203.	1.3	47

#	ARTICLE	IF	CITATIONS
91	Inhibition of the VEGF/VEGFR Pathway Improves Survival in Advanced Kidney Cancer: A Systematic Review and Meta-Analysis. <i>Current Drug Targets</i> , 2015, 16, 164-170.	1.0	47
92	Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. <i>Thorax</i> , 2007, 62, 690-695.	2.7	46
93	Tolerability of first-line therapy for metastatic renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2009, 35, 297-307.	3.4	46
94	Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2010, 36, 16-23.	3.4	46
95	Glomerular diseases and cancer: evaluation of underlying malignancy. <i>Journal of Nephrology</i> , 2016, 29, 143-152.	0.9	45
96	Vitamin K effects in human health: new insights beyond bone and cardiovascular health. <i>Journal of Nephrology</i> , 2020, 33, 239-249.	0.9	44
97	Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. <i>Cancer Treatment Reviews</i> , 2020, 84, 101966.	3.4	44
98	Allopurinol Mouthwashes in the Treatment of 5-Fluorouracil-Induced Stomatitis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1994, 17, 246-247.	0.6	43
99	Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15R α and NKG2D Triggering. <i>Cancer Research</i> , 2014, 74, 68-80.	0.4	43
100	Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 287-294.	0.9	40
101	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. <i>Future Oncology</i> , 2019, 15, 929-941.	1.1	40
102	Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4173.	1.8	40
103	Immunological Effects of Multikinase Inhibitors for Kidney Cancer: A Clue for Integration with Cellular Therapies?. <i>Journal of Cancer</i> , 2011, 2, 333-338.	1.2	39
104	Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. <i>BJU International</i> , 2012, 110, 692-698.	1.3	39
105	Renal cancer in kidney transplanted patients. <i>Journal of Nephrology</i> , 2015, 28, 659-668.	0.9	38
106	Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). <i>Journal of Nephrology</i> , 2017, 30, 171-180.	0.9	38
107	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019, 11, 631-643.	1.0	38
108	Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 490.	2.2	38

#	ARTICLE	IF	CITATIONS
109	New Agents in the Management of Advanced Mesothelioma. <i>Seminars in Oncology</i> , 2005, 32, 336-350.	0.8	37
110	Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma. <i>Biologics: Targets and Therapy</i> , 2008, 2, 601.	3.0	36
111	Management Of Tyrosine Kinase Inhibitorâ€“Induced Handâ€“Foot Skin Reaction: Viewpoints from the Medical Oncologist, Dermatologist, and Oncology Nurse. <i>The Journal of Supportive Oncology</i> , 2011, 9, 13-23.	2.3	36
112	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110196.	1.4	36
113	Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1571-1577.	1.1	35
114	Adjuvant therapy in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2017, 60, 152-157.	3.4	35
115	Renin angiotensin system deregulation as renal cancer risk factor (Review). <i>Oncology Letters</i> , 2017, 14, 5059-5068.	0.8	35
116	Should CARMENA Really Change our Attitude Towards Cyto-reductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cyto-reductive Nephrectomy in the Era of Targeted Therapy. <i>Targeted Oncology</i> , 2018, 13, 705-714.	1.7	35
117	Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets. <i>Pathology</i> , 2020, 52, 297-309.	0.3	35
118	First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. <i>ESMO Open</i> , 2021, 6, 100030.	2.0	35
119	Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. <i>BMC Cancer</i> , 2011, 11, 105.	1.1	34
120	The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 338-348.	1.9	34
121	Renal toxicity of anticancer agents targeting HER2 and EGFR. <i>Journal of Nephrology</i> , 2015, 28, 647-657.	0.9	33
122	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. <i>European Urology</i> , 2022, 81, 266-271.	0.9	33
123	Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancer. <i>BJU International</i> , 2019, 124, 693-700.	1.3	32
124	Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: A critical review. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 323-337.	2.0	31
125	Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review. <i>International Journal of Oncology</i> , 2014, 44, 5-16.	1.4	31
126	Opening an onconephrology clinic: recommendations and basic requirements. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1503-1510.	0.4	31

#	ARTICLE	IF	CITATIONS
127	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 355-359.e1.	0.9	31
128	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2019, 2, 643-648.	2.6	31
129	Novel Insights into Autophagy and Prostate Cancer: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3826.	1.8	31
130	Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 359-366.	2.0	30
131	Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. <i>European Journal of Cancer</i> , 2012, 48, 2983-2992.	1.3	30
132	Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e903-e908.	0.9	30
133	Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4512-4512.	0.8	30
134	Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 14408-14415.	0.8	30
135	A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma. <i>Oncology</i> , 2012, 82, 333-340.	0.9	29
136	Could Interferon Still Play a Role in Metastatic Renal Cell Carcinoma? A Randomized Study of Two Schedules of Sorafenib Plus Interferon-Alpha 2a (RAPSODY). <i>European Urology</i> , 2013, 63, 254-261.	0.9	29
137	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2020, 3, 530-539.	2.6	29
138	The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice. <i>Genes</i> , 2021, 12, 727.	1.0	29
139	Preventive strategies for acute kidney injury in cancer patients. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 70-83.	1.4	28
140	Cytokine-Based Immunotherapy for Advanced Kidney Cancer: Past Results and Future Perspectives in the Era of Molecularly Targeted Agents. <i>Scientific World Journal</i> , The, 2007, 7, 837-849.	0.8	27
141	CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas. <i>British Journal of Cancer</i> , 2017, 117, 947-953.	2.9	27
142	Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma. <i>Oncolimmunology</i> , 2020, 9, 1846901.	2.1	27
143	A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1667-1678.	2.0	27
144	Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC) PISCES study, NCT 01064310.. <i>Journal of Clinical Oncology</i> , 2012, 30, CRA4502-CRA4502.	0.8	27

#	ARTICLE	IF	CITATIONS
145	Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. <i>Anticancer Research</i> , 2007, 27, 165-73.	0.5	27
146	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. <i>Kidney International</i> , 2020, 98, 1108-1119.	2.6	26
147	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. <i>Annals of Oncology</i> , 2015, 26, 2392-2398.	0.6	25
148	Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial. <i>Oncology</i> , 2015, 88, 273-280.	0.9	24
149	Endoplasmic Reticulum Ca ²⁺ Handling and Apoptotic Resistance in Tumor-Derived Endothelial Colony Forming Cells. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 2260-2271.	1.2	24
150	The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 89-99.	2.0	24
151	Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities. <i>Nature Reviews Urology</i> , 2019, 16, 655-673.	1.9	24
152	Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: Analysis Using Diagnostic Nodes. <i>Oncologist</i> , 2015, 20, 1028-1035.	1.9	23
153	Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e84-e91.	0.9	23
154	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 768-780.	5.1	23
155	Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon- γ for metastatic renal cell cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 553-561.	2.0	22
156	Adjuvant Treatment for Resected Renal Cell Carcinoma: Are All Strategies Equally Negative? Potential Implications for Trial Design With Targeted Agents. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 471-476.	0.9	22
157	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). <i>Oncologist</i> , 2019, 24, 491-497.	1.9	22
158	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	1.7	22
159	A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. <i>BJU International</i> , 2011, 107, 1190-1199.	1.3	21
160	Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).. <i>Journal of Clinical Oncology</i> , 2021, 39, 269-269.	0.8	21
161	Granulocyte Dysplasia and Dysfunction, and CD11/CD18 Defects in Myelodysplastic Syndromes. <i>Leukemia and Lymphoma</i> , 1996, 23, 267-275.	0.6	20
162	Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective. <i>Clinical Therapeutics</i> , 2017, 39, 567-580.e2.	1.1	20

#	ARTICLE	IF	CITATIONS
163	The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. <i>Pathology and Oncology Research</i> , 2018, 24, 447-456.	0.9	20
164	Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 783-785.	0.9	20
165	Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6813.	1.8	20
166	Sorafenib tosylate in advanced kidney cancer: past, present and future. <i>Anti-Cancer Drugs</i> , 2009, 20, 409-415.	0.7	19
167	Wide spectrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. <i>Oncotarget</i> , 2017, 8, 7328-7335.	0.8	19
168	Flow cytometric analysis of circulating dendritic cell subsets and intracellular cytokine production in advanced breast cancer patients. <i>Oncology Reports</i> , 2005, 14, 113-20.	1.2	19
169	Cancer Chemotherapy-Related Thrombotic Thrombocytopenic Purpura: Biological Evidence of Increased Nitric Oxide Production. <i>Mayo Clinic Proceedings</i> , 1999, 74, 570-574.	1.4	18
170	Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro. <i>Journal of Cellular Physiology</i> , 2000, 185, 126-134.	2.0	18
171	How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 227-233.	1.1	18
172	Acute Kidney Injury in Cancer Patients. <i>Contributions To Nephrology</i> , 2018, 193, 137-148.	1.1	18
173	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. <i>ESMO Open</i> , 2020, 5, e000852.	2.0	18
174	Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2018, 70, 112-117.	3.4	17
175	Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells. <i>Cytotechnology</i> , 2019, 71, 149-163.	0.7	17
176	Large Extracellular Vesicles "A New Frontier of Liquid Biopsy in Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6543.	1.8	17
177	Cabozantinib for the treatment of solid tumors: a systematic review. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211071.	1.4	17
178	Use of Sorafenib in Two Metastatic Renal Cell Cancer Patients with End-Stage Renal Impairment Undergoing Replacement Hemodialysis. <i>Tumori</i> , 2009, 95, 542-544.	0.6	16
179	Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. <i>Hepatic Oncology</i> , 2014, 1, 181-188.	4.2	16
180	Tivantinib (ARQ197) in hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 615-622.	1.1	16

#	ARTICLE	IF	CITATIONS
181	Intracellular Chloride Ion Channel Protein-1 Expression in Clear Cell Renal Cell Carcinoma. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 299-307.	1.0	16
182	Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines. <i>Journal of Nephrology</i> , 2019, 32, 57-64.	0.9	16
183	An Anti-MICA/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3583.	1.7	16
184	Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for?. <i>Cancer Treatment Reviews</i> , 2021, 94, 102157.	3.4	16
185	Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art. <i>Cancers</i> , 2021, 13, 3091.	1.7	16
186	Uterine carcinosarcoma: An overview. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103369.	2.0	16
187	ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics. <i>Annals of Translational Medicine</i> , 2016, 4, S14-S14.	0.7	16
188	Docetaxel, Carboplatin and Concomitant Radiotherapy for Unresectable Squamous Cell Carcinoma of the Head and Neck. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 155-163.	0.6	15
189	How to Identify Active Novel Agents in Rare Cancers and then Make Them Available: A Need for a Paradigm Shift. <i>European Urology</i> , 2012, 62, 1020-1021.	0.9	15
190	Toward a genome-based treatment landscape for renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 141-152.	2.0	15
191	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 477-488.	0.9	15
192	Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 50-59.	2.0	14
193	The role of tivozanib in advanced renal cell carcinoma therapy. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1113-1124.	1.1	14
194	Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019, 37, 581-581.	0.8	14
195	Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib. <i>World Journal of Hepatology</i> , 2010, 2, 103.	0.8	14
196	Sequential intrahepatic and systemic fluoropyrimidine-based chemotherapy for metastatic colorectal cancer confined to the liver. A phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 423-428.	1.1	13
197	Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study. <i>Future Oncology</i> , 2012, 8, 1605-1612.	1.1	13
198	Weekly taxanes in metastatic breast cancer (review). <i>Oncology Reports</i> , 2002, 9, 1047-52.	1.2	13

#	ARTICLE	IF	CITATIONS
199	Thrombotic thrombocytopenic purpura (TTP): Retrospective study of 84 patients and therapeutic prospects. <i>Transfusion Science</i> , 1992, 13, 39-44.	0.6	12
200	Allopurinol mouthwashes in methotrexate-induced stomatitis. <i>Arthritis and Rheumatism</i> , 1994, 37, 777-778.	6.7	12
201	Bevacizumab plus Interferon- γ versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy. <i>Clinical Drug Investigation</i> , 2011, 31, 507-517.	1.1	12
202	Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. <i>Future Oncology</i> , 2014, 10, 1741-1750.	1.1	12
203	Metastatic renal cell carcinoma cells growing in 3D on poly-D-lysine or laminin present a stem-like phenotype and drug resistance. <i>Oncology Reports</i> , 2019, 42, 1878-1892.	1.2	12
204	Targeting angiogenesis in metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 245-257.	1.1	12
205	Prognostic Factors and Current Treatment Strategies for Renal Cell Carcinoma Metastatic to the Brain: An Overview. <i>Cancers</i> , 2021, 13, 2114.	1.7	12
206	Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system. <i>BMJ Open</i> , 2021, 11, e049128.	0.8	12
207	The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma. <i>Future Oncology</i> , 2012, 8, 1051-1057.	1.1	11
208	Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 6-12.e4.	0.9	11
209	Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societ� Italiana di Nefrologia (SIN) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 39-51.	2.0	11
210	COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 425-435.e4.	0.9	11
211	Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e588-e597.	0.9	11
212	The heterogeneity of cancer endothelium: The relevance of angiogenesis and endothelial progenitor cells in cancer microenvironment. <i>Microvascular Research</i> , 2021, 138, 104189.	1.1	11
213	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 33381-33390.	0.8	11
214	EOSINOPHILS AND SERUM EOSINOPHILIC CATIONIC PROTEINS IN INTERLEUKIN-2-BASED IMMUNOTHERAPY FOR CANCER. <i>British Journal of Haematology</i> , 1998, 100, 607-608.	1.2	10
215	Re: Damien Pouessel, St�phane Culine. High Frequency of Intracerebral Hemorrhage in Metastatic Renal Carcinoma Patients with Brain Metastases Treated with Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor Receptor. <i>Eur Urol</i> 2008;53:376-81. <i>European Urology</i> , 2008, 53, 1092-1093.	0.9	10
216	Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis. <i>Future Oncology</i> , 2015, 11, 3159-3166.	1.1	10

#	ARTICLE	IF	CITATIONS
217	Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line. Expert Opinion on Pharmacotherapy, 2016, 17, 643-655.	0.9	10
218	Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)1. Kidney Cancer, 2018, 2, 31-36.	0.2	10
219	Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review. Critical Reviews in Oncology/Hematology, 2019, 139, 149-157.	2.0	10
220	Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). Tumori, 2019, 105, 3-12.	0.6	10
221	Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison. Critical Reviews in Oncology/Hematology, 2019, 139, 143-148.	2.0	10
222	Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.. Journal of Clinical Oncology, 2019, 37, 564-564.	0.8	10
223	Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. World Journal of Gastroenterology, 2017, 23, 2448.	1.4	10
224	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210795.	1.4	10
225	Autoimmunity in Thrombotic Thrombocytopenic Purpura. Seminars in Thrombosis and Hemostasis, 2005, 31, 633-640.	1.5	9
226	Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. Cancer Treatment Reviews, 2012, 38, 127-132.	3.4	9
227	Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity. Clinical Genitourinary Cancer, 2014, 12, 262-269.	0.9	9
228	Transplantation of kidneys with tumors. Journal of Nephrology, 2016, 29, 163-168.	0.9	9
229	Introduction to the Journal of Onco-Nephrology. Journal of Onco-Nephrology, 2017, 1, 1-4.	0.3	9
230	Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. Future Oncology, 2018, 14, 1347-1354.	1.1	9
231	Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies. ESMO Open, 2020, 5, e000618.	2.0	9
232	Primary Soft Tissue Sarcoma of the Heart: An Emerging Chapter in Cardio-Oncology. Biomedicines, 2021, 9, 774.	1.4	9
233	Liquid Biopsy in Cervical Cancer: Hopes and Pitfalls. Cancers, 2021, 13, 3968.	1.7	9
234	Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives. Cancer Treatment Reviews, 2021, 100, 102288.	3.4	9

#	ARTICLE	IF	CITATIONS
235	The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?. PLoS ONE, 2015, 10, e0120427.	1.1	9
236	Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2020, 38, 642-642.	0.8	9
237	Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations. Cancer Treatment Reviews, 2022, 105, 102379.	3.4	9
238	Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: A possible mechanism of interleukin-2-mediated cytotoxicity?. Lung Cancer, 2002, 38, 159-162.	0.9	8
239	Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions. Future Oncology, 2016, 12, 533-549.	1.1	8
240	Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. Clinical Genitourinary Cancer, 2016, 14, 406-414.	0.9	8
241	Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, 39-43.	0.6	8
242	Renal cell carcinoma treatment after first-line combinations. Lancet Oncology, The, 2019, 20, 1332-1334.	5.1	8
243	KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. Kidney International, 2020, 98, 1407-1418.	2.6	8
244	Exploring the Spectrum of Kidney Ciliopathies. Diagnostics, 2020, 10, 1099.	1.3	8
245	Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.. Journal of Clinical Oncology, 2021, 39, 313-313.	0.8	8
246	Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. European Journal of Cancer, 2021, 155, 56-63.	1.3	8
247	SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinationsâ€”consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM). Radiologia Medica, 2022, 127, 534-542.	4.7	8
248	Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. European Journal of Cancer, 2022, 172, 191-198.	1.3	8
249	Effect of different platelet agonists on intracellular free CA++ concentrations in human tumor cells: Possible role in tumor growth. International Journal of Cancer, 1995, 62, 291-296.	2.3	7
250	Nitrate Plasma Level as a Marker of Nitric Oxide Production After Subcutaneous Interleukin 2 Immunotherapy. Journal of the National Cancer Institute, 1997, 89, 1545-1545.	3.0	7
251	Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor. Future Oncology, 2013, 9, 831-843.	1.1	7
252	Considerations for the Design of Future Clinical Trials in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 1-12.	0.9	7

#	ARTICLE	IF	CITATIONS
253	Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 144, 102812.	2.0	7
254	Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 581130.	1.3	7
255	MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. <i>Journal of Clinical Pathology</i> , 2022, 75, 39-44.	1.0	7
256	Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. <i>European Urology Oncology</i> , 2021, 4, 274-281.	2.6	7
257	Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma. <i>Cells</i> , 2022, 11, 17.	1.8	7
258	â€˜Tunelâ€™™ evidence of reduced bone marrow cells apoptosis in a refractory anaemia patient treated with amifostine. <i>British Journal of Haematology</i> , 1999, 104, 424-425.	1.2	6
259	Entropy Increases in Kidney Cancer Treatment, but a Bit of Simplicity May Emerge From Chaos. <i>European Urology</i> , 2011, 60, 1171-1172.	0.9	6
260	Axitinib dose titration: what's the limiting factor?. <i>Lancet Oncology</i> , The, 2013, 14, 1152-1154.	5.1	6
261	Tivantinib, a New Option for Second-line Treatment of Advanced Hepatocellular Carcinoma? The Experience of Italian Centers. <i>Tumori</i> , 2015, 101, 139-143.	0.6	6
262	Application of â€œomicsâ€ sciences to the prediction of bone metastases from breast cancer: State of the art. <i>Journal of Bone Oncology</i> , 2021, 26, 100337.	1.0	6
263	Second-line treatment in renal cell carcinoma: clinical experience and decision making. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110228.	0.9	6
264	The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 339-339.	0.8	6
265	Playing the Devilâ€™s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? â€œ ie Strategies to Revert Resistance to mTOR Inhibitors. <i>Cancer Management and Research</i> , 2021, Volume 13, 7623-7636.	0.9	6
266	Impact of topotecan-based chemotherapy on the immune system of advanced ovarian cancer patients: an immunophenotypic study. <i>Oncology Reports</i> , 2002, 9, 1107-13.	1.2	6
267	Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone. <i>International Journal of Molecular Medicine</i> , 2003, 11, 161-7.	1.8	6
268	HLA-A, B, C, DR and DQ expression and hepatocellular carcinoma: study of 205 Italian subjects. <i>Cancer Letters</i> , 1995, 98, 121-125.	3.2	5
269	Possible efficacy of allopurinol vaginal washings in the treatment of chemotherapy-induced vaginitis. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 41, 171-172.	1.1	5
270	Adding raltitrexed to cisplatin improves overall survival in people with malignant pleural mesothelioma. <i>Cancer Treatment Reviews</i> , 2006, 32, 229-233.	3.4	5

#	ARTICLE	IF	CITATIONS
271	Sequencing or not sequencing multikinase inhibitors in kidney cancer: this is the dilemma. <i>Oncology Reviews</i> , 2010, 4, 1-3.	0.8	5
272	Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. <i>ClinicoEconomics and Outcomes Research</i> , 2011, 3, 19.	0.7	5
273	Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1089-1096.	1.1	5
274	SORAFENIB RECHALLENGE IN METASTATIC RENAL CELL CARCINOMA. <i>BJU International</i> , 2012, 110, E235.	1.3	5
275	Harmonization of Renal Function Assessment Is Needed Throughout the Whole Process of Anticancer Drug Development. <i>Journal of Clinical Oncology</i> , 2016, 34, 2429-2430.	0.8	5
276	Pharmacotherapy for treating metastatic clear cell renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 205-216.	0.9	5
277	Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient. <i>Frontiers in Pharmacology</i> , 2017, 8, 329.	1.6	5
278	The effect of a treatment delay on outcome in metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 529.e1-529.e7.	0.8	5
279	Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research. <i>Translational Oncology</i> , 2021, 14, 101153.	1.7	5
280	Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2021, , 1-9.	1.4	5
281	Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients. <i>Oncology Reports</i> , 2005, 13, 689-95.	1.2	5
282	Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 285-295.	0.9	5
283	Anti-HCV Antibodies and Hepatocellular Carcinoma. <i>Upsala Journal of Medical Sciences</i> , 1992, 97, 261-266.	0.4	4
284	Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 141-152.	1.1	4
285	Optimizing treatment for metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1901-1911.	1.1	4
286	Urea-Based Cream to Prevent Sorafenib-Induced Hand-and-Foot Skin Reaction: Which Evidence?. <i>Journal of Clinical Oncology</i> , 2015, 33, 3219-3220.	0.8	4
287	Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 151-162.	1.4	4
288	An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy. <i>Journal of Medical Economics</i> , 2020, 23, 1579-1587.	1.0	4

#	ARTICLE	IF	CITATIONS
289	Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?. <i>Current Opinion in Urology</i> , 2021, 31, 236-241.	0.9	4
290	Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?. <i>Oncology Reviews</i> , 2021, 15, 564.	0.8	4
291	Consistent efficacy of nivolumab plus ipilimumab across number of International Metastatic Database Consortium (IMDC) risk factors in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4575-4575.	0.8	4
292	Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis. <i>Tumori</i> , 2009, 95, 542-4.	0.6	4
293	High-dose human immunoglobulins in thrombotic thrombocytopenic purpura. <i>American Journal of Hematology</i> , 1994, 45, 99-100.	2.0	3
294	Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. <i>Cancer</i> , 1995, 75, 2782-2784.	2.0	3
295	Nitrite and Nitrate Plasma Levels, as Markers for Nitric Oxide Synthesis, in Thrombotic Thrombocytopenic Purpura (TTP). <i>Hematology</i> , 1996, 1, 239-246.	0.7	3
296	Thrombotic Thrombocytopenic Purpura and Relapses: Why do case series differ?. <i>American Journal of Hematology</i> , 1996, 52, 215-216.	2.0	3
297	TREATMENT OF METASTATIC RENAL CARCINOMA PATIENTS WITH THE COMBINATION OF GEMCITABINE, CAPECITABINE AND BEVACIZUMAB AT A TERTIARY CANCER CENTRE. <i>BJU International</i> , 2011, 107, 747-748.	1.3	3
298	Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximab. <i>Immunotherapy</i> , 2011, 3, 487-490.	1.0	3
299	Evidence and experience for the management of metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , Supplement, 2013, 11, 1-8.	2.2	3
300	Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study. <i>BJU International</i> , 2017, 119, 846-853.	1.3	3
301	Urothelial cancer: Once there were urologists, now oncologists joined, what about nephrologists?. <i>Journal of Onco-Nephrology</i> , 2018, 2, 3-5.	0.3	3
302	Medical Treatment of Advanced Hepatocellular Carcinoma Patients: The Issue Is Not the Right Drug, but the Right Patient. <i>Hepatology</i> , 2019, 70, 429-430.	3.6	3
303	Immune-based combination therapy for metastatic kidney cancer. <i>Nature Reviews Nephrology</i> , 2019, 15, 324-325.	4.1	3
304	Conventional chemotherapy. , 2020, , 127-153.e11.		3
305	The basics of onco-nephrology in the renal clinic. <i>Journal of Nephrology</i> , 2020, 33, 1143-1149.	0.9	3
306	An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2199-2204.	0.9	3

#	ARTICLE	IF	CITATIONS
307	Editorial debate: Challenges an oncologist has to face during the SARS-CoV-2 pandemic within a universal healthcare system. <i>ESMO Open</i> , 2020, 5, e000790.	2.0	3
308	The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability. <i>Journal of Neuroendocrinology</i> , 2021, 33, e13041.	1.2	3
309	TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5062-5062.	0.8	3
310	GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110543.	0.9	3
311	RAMES study: is there really a role for VEGF inhibition in mesothelioma?. <i>Lancet Oncology</i> , The, 2021, 22, e532.	5.1	3
312	A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer. <i>Anticancer Research</i> , 2013, 33, 4999-5004.	0.5	3
313	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 727.	1.1	3
314	Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®). <i>Tumori</i> , 0, , 030089162210995.	0.6	3
315	Autoantibody profile in thrombotic thrombocytopenic purpura. <i>Transfusion Science</i> , 1992, 13, 33-36.	0.6	2
316	Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials.. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 254-263.	2.0	2
317	The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2018, 29, 705-709.	0.7	2
318	Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial. <i>Tumori</i> , 2020, 106, 257-266.	0.6	2
319	TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib.. <i>Journal of Clinical Oncology</i> , 2021, 39, 278-278.	0.8	2
320	Sorafenib and hepatocellular carcinoma: is alpha-fetoprotein a biomarker predictive of tumor biology and primary resistance?. <i>Future Oncology</i> , 2021, 17, 3579-3584.	1.1	2
321	Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5071-5071.	0.8	2
322	Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 441-450.	3.0	2
323	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. <i>World Journal of Clinical Oncology</i> , 2021, 12, 1037-1046.	0.9	2
324	Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients. <i>Oncology Reports</i> , 2004, 12, 855-9.	1.2	2

#	ARTICLE	IF	CITATIONS
325	Immunological stress in kidney cancer patients undergoing either open nephrectomy or nephron-sparing surgery: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. <i>Oncology Reports</i> , 2008, 20, 1511-9.	1.2	2
326	A Glimpse in the Future of Malignant Mesothelioma Treatment. <i>Frontiers in Pharmacology</i> , 2021, 12, 809337.	1.6	2
327	Redistribution of CD8+ T cell subsets in metastatic renal cell carcinoma patients treated with anti-PD-1 therapy. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2022, 101, 597-605.	1.1	2
328	Abemaciclib for malignant pleural mesothelioma. <i>Lancet Oncology</i> , The, 2022, 23, e237.	5.1	2
329	Maturation of overall survival (OS) in TIVO-3 with long-term follow-up.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4557-4557.	0.8	2
330	Allogeneic transplantation following non-myeloablative conditioning in renal carcinoma. New evidence of the immune mechanisms responsible for the activity of this form of immunotherapy and the pathogenetic role of endogenous retroviruses. <i>Oncology Reviews</i> , 2008, 2, 1-3.	0.8	1
331	Prognostic factors in advanced renal cell cancer. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 35-37.	2.2	1
332	mRCC management: past, present and future. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 1-11.	2.2	1
333	Sequential therapy in metastatic renal cell carcinoma: what comes next?. <i>Medical Oncology</i> , 2012, 29, 1914-1915.	1.2	1
334	Case Report: Long-Lasting Response in a Patient with Metastatic Renal Cell Cancer Receiving Antitumor Cytotoxic T Lymphocytes. <i>Tumori</i> , 2013, 99, e282-e284.	0.6	1
335	Reply to S. Barni et al and M. Sun et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 3783-3784.	0.8	1
336	Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. <i>Eur Urol</i> 2019;75:111-118. <i>European Urology Oncology</i> , 2019, 2, 603-604.	2.6	1
337	THU-482-A human anti-MICA/B antibody boost NK cell responses in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, e373.	1.8	1
338	Acute Kidney Injury in Oncology and Tumor Lysis Syndrome. , 2019, , 234-250.e1.		1
339	Mammalian Targets of Rapamycin Inhibitors: Temsirolimus and Everolimus. , 2017, , 273-294.		1
340	TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4572-4572.	0.8	1
341	Long-term safety of targeted agents used to treat metastatic renal cell carcinoma: the issue is not the rate of adverse events over time, but the expertise needed to manage them. <i>Translational Cancer Research</i> , 2016, 5, S613-S615.	0.4	1
342	Renal Cancer. <i>UNIPA Springer Series</i> , 2021, , 755-774.	0.1	1

#	ARTICLE	IF	CITATIONS
343	Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?. <i>Annals of Translational Medicine</i> , 2019, 7, S15-S15.	0.7	1
344	An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the "Pamerita"™ study. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 484-491.	0.6	1
345	Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trial. <i>Translational Andrology and Urology</i> , 2012, 1, 120-2.	0.6	1
346	Biliary tract cancers: moving from the present standards of care towards the use of immune checkpoint inhibitors. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 8598-8610.	0.0	1
347	Renal cell carcinoma and viral infections: A dangerous relationship?. <i>World Journal of Nephrology</i> , 2022, 11, 1-12.	0.8	1
348	Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma: The "eretry" study from the Italian Group of Onco-Nephrology (G.I.O.N.). <i>Journal of Onco-Nephrology</i> , 2022, 6, 107-114.	0.3	1
349	Nephrectomy as a component of systemic treatment for renal cell carcinoma patients. <i>Journal of Surgical Oncology</i> , 1994, 56, 81-82.	0.8	0
350	ASCO 2007: "Translating Research into Practice" Report from the 34th annual meeting of the American Society of Clinical Oncology. <i>Oncology Reviews</i> , 2007, 1, 65-72.	0.8	0
351	Oncology reviews: reasons for a new oncology journal. <i>Oncology Reviews</i> , 2007, 1, 1-2.	0.8	0
352	To fast or not to fast? How food could impact on the absorption of kinase inhibitors and its economical value. <i>Oncology Reviews</i> , 2007, 1, 129-130.	0.8	0
353	How to predict the development of hepatocellular carcinoma in cirrhotic patients. Despite recent advances, the search continues. <i>Oncology Reviews</i> , 2008, 1, 187-188.	0.8	0
354	The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia. <i>Oncology Reviews</i> , 2008, 2, 67-68.	0.8	0
355	Hepatitis b virus genotype and mutants and the risk of hepatocellular carcinoma. <i>Oncology Reviews</i> , 2008, 2, 129-130.	0.8	0
356	Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancer. <i>Oncology Reviews</i> , 2009, 3, 1-2.	0.8	0
357	Surgery and Target Agents for Renal Cell Carcinoma Treatment: The Path between Proper Interaction. <i>Urologia</i> , 2011, 78, 9-15.	0.3	0
358	Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time. <i>Oncology Reviews</i> , 2011, 5, 141-142.	0.8	0
359	Reply to Giuseppe Procopio, Elena Verzoni and Filippo De Braud's Letter to the Editor re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and Safety of Everolimus in Elderly Patients with Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. <i>Eur Urol</i> 2012;61:826-33. <i>European Urology</i> , 2012, 62, e7-e8.	0.9	0
360	From the Zeno's paradoxes to novel immunotherapeutic agents for kidney cancer: moving from an era of wrong premises and conclusions to a better comprehension of immunology. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 813-815.	1.4	0

#	ARTICLE	IF	CITATIONS
361	Predicting efficacy of sunitinib in metastatic renal cell carcinoma. <i>Current Biomarker Findings</i> , 2014, , 43.	0.4	0
362	Slow and Steady Wins the Race: Practical (and Philosophical) Considerations of Treatment Activity Evaluation When Novel Anticancer Agents Just Slow Neoplastic Progression. <i>European Urology</i> , 2014, 65, 721-722.	0.9	0
363	Editorial Comment from Dr Porta <i>et al</i> . to Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the <i>USA</i> . <i>International Journal of Urology</i> , 2017, 24, 279-280.	0.5	0
364	Costo-Efficacia di cabozantinib nel trattamento di seconda linea del tumore a cellule renali metastatico (mRCC) in Italia. <i>Global & Regional Health Technology Assessment</i> , 2018, 2018, 228424031879073.	0.2	0
365	Treatment sequencing strategies in metastatic renal cell carcinoma: A critical interpretation of available data. <i>Journal of Onco-Nephrology</i> , 2020, 4, 153-164.	0.3	0
366	738P Soluble PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTN2A1 as predictive biomarkers of nivolumab response in patients with metastatic clear cell renal carcinoma. <i>Annals of Oncology</i> , 2020, 31, S575.	0.6	0
367	Chronic kidney disease as a complication of cancer, with special focus on kidney and urothelial tumors. , 2020, , 299-306.e1.		0
368	Targeted RNA-seq signature of breast cancer (BC) circulating tumor cells (CTCs) correlates with the onset of bone-only metastases. <i>Bone Reports</i> , 2021, 14, 100840.	0.2	0
369	Impact of SARS-CoV-2 Pandemic on Kidney Cancer Management. <i>Kidney Cancer</i> , 2021, 5, 93-106.	0.2	0
370	Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time. <i>Oncology Reviews</i> , 2011, 5, 141.	0.8	0
371	Renal Cell Carcinoma: From Molecular Biology to Targeted Therapies. , 2015, , 555-575.		0
372	TIVO-3: A Phase 3, Randomised, Open-Label Study Comparing Tivozanib to Sorafenib in Patients with Advanced Renal Cell Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
373	Integrating liquid biopsy with advanced imaging analysis to improve the prediction of response to immunotherapy in patients with NSCLC.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14054-e14054.	0.8	0
374	A novel predictive biomarker of immunotherapy response in metastatic renal cell carcinoma (mRCC): The lymphocyte microRNA expression profile.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16109-e16109.	0.8	0
375	Safety and efficacy of tivozanib in first-line metastatic renal cell carcinoma: A multicenter compassionate use study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 632-632.	0.8	0
376	MP14-12â€fSTEREOTACTIC ABLATIVE RADIATION THERAPY (SABR) FOR TREATMENT OF RENAL CELL CARCINOMA (RCC) WITH INFERIOR VENA CAVA TUMOR THROMBUS (IVC-TT). <i>Journal of Urology</i> , 2020, 203, .	0.2	0
377	Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5070-5070.	0.8	0
378	Abstract P1-17-09: Cardiotoxicity and overall safety profile of adjuvant chemotherapy in elderly breast cancer patients: A cohort study. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
379	Psychosocial impact of COVID-19 pandemic on cancer patients with bone metastases (PsyCO-B): a multicentre prospective observational study. Bone Reports, 2022, 16, 101371.	0.2	0
380	Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma. Clinical Drug Investigation, 0, , .	1.1	0
381	The prognostic value of peripheral blood inflammatory indices early variation in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with nivolumab (I ⁹² -Meet-URO analysis).. Journal of Clinical Oncology, 2022, 40, 4534-4534.	0.8	0